PF-3758309

Research use only, not for human use.

PF-03758309 (IC50=1.3 nM), a pyrrolopyrazole inhibitor of PAK4, has effective ATP-competition.

PF-03758309 (IC50=1.3 nM), a pyrrolopyrazole inhibitor of PAK4, has effective ATP-competition.

PF-3758309 has similar enzymatic potency against the kinase domains of the other group B PAKs (PAK5, Ki=18.1 nM; PAK6, Ki=17.1 nM) and group A PAK1 (Ki=13.7 nM), but is less active against the other two group A PAKs (PAK2, IC50=190 nM; PAK3, IC50=99 nM). In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50=1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50=4.7 nM). PF-3758309 also inhibits endogenous pGEF-H1 accumulation in HCT116 cells. PF-3758309 potently inhibits cellular proliferation (IC50=20 nM) and anchorage-independent growth (IC50=27 nM) of A549 cells.

PF-3758309 (7.5-30 mg/kg; p.o.; twice daily for 9-18 days) results in statistically significant tumor growth inhibition (TGI) in HCT116 and A549 models. Animal Model:Female nu/nu, CRL breed 6–8 weeks old mice (bearing HCT116 and A549 tumors)Dosage:7.5-30 mg/kg Administration:Oral administration; twice daily for 9-18 daysResult:Significant tumor growth inhibition (TGI) in HCT116 and A549 models.

——

Membrane Transporter/Ion Channel

NMDAR

PAK1| PAK3| PAK4| PAK5| PAK6

Cancer

——

898044-15-0

490.62

C25H30N8OS

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 203.82 mM

CN(C)C[C@@H](NC(=O)N1Cc2c([nH]nc2Nc2nc(C)nc3c2scc3)C1(C)C)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years